Skip to main content
SpringerLink
Log in

Complications and Special Presentations of Plasma Cell Myeloma

  • Chapter
  • First Online:
Book cover Neoplastic Diseases of the Blood

Abstract

The plasma cell proliferation in multiple myeloma (MM) is characterized by an increased number of bone marrow plasma cells and extensive skeletal involvement with lytic bone lesions and/or severe osteoporosis resulting in anemia, pathological or compression fractures, hypercalcemia and/or extramedullary plasmacytomas. The excessive production of M-protein can result in renal failure due to myeloma kidney (precipitation of light chains within the distal and collecting tubules—myeloma cast formation), recurrent bacterial infections mainly due to a decrease in polyclonal immunoglobulins, or associated amyloidosis. In this chapter the more common complications and the special presentations of plasma cell myeloma are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    Article  PubMed  Google Scholar 

  2. Terpos E, Cibeira MT, Bladé J, Ludwig H. Management of complications in multiple myeloma. Semin Hematol. 2009;46:176–89.

    Article  PubMed  CAS  Google Scholar 

  3. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol. 1998;103:902–10.

    Article  PubMed  CAS  Google Scholar 

  4. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223–31.

    Article  PubMed  CAS  Google Scholar 

  5. Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 1999;93:300–5.

    PubMed  CAS  Google Scholar 

  6. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1117–25.

    Article  PubMed  CAS  Google Scholar 

  7. Roux S, Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kB) and RANK ligand expression. Leuk Lymphoma. 2004;45: 1111–8.

    Article  PubMed  CAS  Google Scholar 

  8. Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101:2094–8.

    Article  PubMed  CAS  Google Scholar 

  9. Tian E, Zhan F, Walker R, et al. The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483–94.

    Article  PubMed  CAS  Google Scholar 

  10. Bladé J, Rosiñol L. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1231–46.

    Article  PubMed  Google Scholar 

  11. McDonald RJ, Trout AT, Gray LA, et al. Vertebroplasty in multiple myeloma: outcome in a large patient series. AJNR Am J Neuroradiol. 2008;29:642–8.

    Article  PubMed  CAS  Google Scholar 

  12. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a resulto f multiple myeloma. J Clin Oncol. 2002;20:2382–7.

    Article  PubMed  CAS  Google Scholar 

  13. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–67.

    PubMed  CAS  Google Scholar 

  14. Latineen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finís Leukemia Group. Lancet. 1992;340:1049–52.

    Article  Google Scholar 

  15. McCloskey EV, Duna JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035–43.

    Article  PubMed  CAS  Google Scholar 

  16. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with multiple myeloma. N Engl J Med. 1996;334:488–93.

    Article  PubMed  CAS  Google Scholar 

  17. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol. 1998;16:593–602.

    PubMed  CAS  Google Scholar 

  18. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–87.

    PubMed  CAS  Google Scholar 

  19. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–7.

    Article  PubMed  Google Scholar 

  20. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968–71.

    PubMed  CAS  Google Scholar 

  21. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma: clinical features and risk factor. J Clin Oncol. 2006;24:945–52.

    Article  PubMed  CAS  Google Scholar 

  22. Badros A, Terpos E, Katoditrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904–9.

    Article  PubMed  Google Scholar 

  23. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of the osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117–20.

    Article  PubMed  CAS  Google Scholar 

  24. Markowitz GS, Fine PL, D’agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39:1118–22.

    Article  PubMed  Google Scholar 

  25. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464–72.

    Article  PubMed  CAS  Google Scholar 

  26. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047–53.

    Article  PubMed  CAS  Google Scholar 

  27. Harousseau JL, Greil R, Kloke O. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16 Suppl 1:i45–7.

    Article  Google Scholar 

  28. Durie BGM. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516–7.

    Article  PubMed  Google Scholar 

  29. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations o fan expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303–17.

    Article  PubMed  CAS  Google Scholar 

  30. Alexanian R, Balogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med. 1990;150:1693–5.

    Article  PubMed  CAS  Google Scholar 

  31. Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in ­multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889–93.

    Article  PubMed  Google Scholar 

  32. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on prognosis. Nordic Myeloma study Group. Eur J Haematol. 2000;65:175–81.

    Article  PubMed  CAS  Google Scholar 

  33. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337–41.

    Article  PubMed  CAS  Google Scholar 

  34. Torra R, Bladé J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy and outcome in a series of 20 cases. Br J Haematol. 1995;91:854–9.

    Article  PubMed  CAS  Google Scholar 

  35. Dimopoulos MA, Kastritis E, Rosiñol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.

    Article  PubMed  CAS  Google Scholar 

  36. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992;89:630–9.

    Article  PubMed  CAS  Google Scholar 

  37. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845–51.

    Article  PubMed  CAS  Google Scholar 

  38. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol. 2007;153:87–104.

    Article  PubMed  CAS  Google Scholar 

  39. Comenzo RL, Zhang Y, Martínez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L)germ line gene use and clonal plasma cell burden. Blood. 2001;98:714–20.

    Article  PubMed  CAS  Google Scholar 

  40. Merlíni G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.

    Article  PubMed  Google Scholar 

  41. Obici L, Perfetti V, Palladini G, Moratti R, Merlíni G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753:11–22.

    Article  PubMed  CAS  Google Scholar 

  42. Randall RE, Williamson WC, Mullinanx F, Tung MY, Still WJS. Manifestations of light chain deposition. Am J Med. 1976;60:293–9.

    Article  PubMed  CAS  Google Scholar 

  43. Dhodapkar MV, Merlín G, Solomon A. Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am. 1997;11:89–110.

    Article  PubMed  CAS  Google Scholar 

  44. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13:1235–48.

    Article  PubMed  CAS  Google Scholar 

  45. Pozzi C, D’Amico M, Fogazzi CB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154–63.

    Article  PubMed  Google Scholar 

  46. Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004;104:40–2.

    Article  PubMed  CAS  Google Scholar 

  47. Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone containing regimens and the impact of novel agents. Haematologica. 2007;92:546–9.

    Article  PubMed  CAS  Google Scholar 

  48. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9:302–6.

    Article  PubMed  CAS  Google Scholar 

  49. Ludwig H, Adam Z, Hajek R, et al. Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study. Blood. 2007;110(11 Suppl):3603. Abstract.

    Google Scholar 

  50. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma. Analysis of patients entered onto the United Kingdom Medical Research Council Adult Leukemia Working Party. J Clin Oncol. 2005;23:9219–26.

    Article  PubMed  Google Scholar 

  51. Chanan-Khan AA, Kaufman JL, Metha J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure. A multicenter retrospective study. Blood. 2007;109:2604–6.

    Article  PubMed  CAS  Google Scholar 

  52. Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of the Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84:223–8.

    Article  PubMed  CAS  Google Scholar 

  53. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27:6086–93.

    Article  PubMed  CAS  Google Scholar 

  54. Dimopoulos MA, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116(16):3807–14.

    Article  PubMed  CAS  Google Scholar 

  55. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Heamatol. 2001;114:822–9.

    Article  CAS  Google Scholar 

  56. Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39:605–11.

    Article  PubMed  CAS  Google Scholar 

  57. Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150:863–9.

    Article  PubMed  CAS  Google Scholar 

  58. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777–84.

    PubMed  Google Scholar 

  59. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free Light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886–95.

    Article  PubMed  CAS  Google Scholar 

  60. Bladé J, San Miguel JF, Fontanillas M, et al. Initial treatment of multiple myeloma: long-term results in 914 patients. Hematol J. 2001;2:272–8.

    Article  PubMed  Google Scholar 

  61. Bladé J. Management of renal, hematologic, and infectious complications. In: Malpas JS, Bergsagel DE, Kyle RA, editors. Myeloma: biology and management. 3rd ed. Philadelphia, PA: Saunders, Elsevier; 2004. p. 251–67.

    Google Scholar 

  62. Mecharchand J. Management of haematological complications of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, editors. 2nd edition. Oxford: Oxford University Press; 2000. p. 332–57.

    Google Scholar 

  63. Berguin Y, Yerna M, Loo M, et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82:648–53.

    Article  Google Scholar 

  64. Bladé J, Dimopoulos MA, Rosiñol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria and follow-up recommendations. J Clin Oncol. 2010;28:690–7.

    Article  PubMed  CAS  Google Scholar 

  65. Bergsagel DE, Bailey AL, Langley GR, et al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743–8.

    Article  PubMed  CAS  Google Scholar 

  66. Cuzick J, Erskine S, Edelman D, et al. A comparison of the incidence of myelodysplastic syndrome and acute leukemia following melphalan and cyclophosphamide treatment for multiple myeloma. Br J Cancer. 1987;55:523–9.

    Article  PubMed  CAS  Google Scholar 

  67. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants in multiple myeloma. Br J Haematol. 1996;95:349–53.

    Article  PubMed  CAS  Google Scholar 

  68. Cleeland CS, Demetri GD, Glaspi J, et al. Identifying hemoglobin level for optimal quality of life. Results from an incremental analysis. J Clin Oncol. 1999;8:574a.

    Google Scholar 

  69. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132–49.

    Article  PubMed  CAS  Google Scholar 

  70. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Blood. 2008;111:25–41.

    Article  PubMed  CAS  Google Scholar 

  71. Bergsagel DE. Plasma cell neoplasms anda cute leukemia. Clin Haematol. 1982;11:221–34.

    PubMed  CAS  Google Scholar 

  72. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40.

    PubMed  CAS  Google Scholar 

  73. Kelleher P, Chapel H. Infections: principle of prevention and therapy. In: Metha J, Singhal S, editors. Myeloma. London: Martin Dunits; 2002. p. 223–39.

    Google Scholar 

  74. Zinneman HH, Hall WH. Recurent pneumonia in multiple myeloma and some observations on immunological response. Ann Intern Med. 1954;41:1152–63.

    PubMed  CAS  Google Scholar 

  75. Glenchur H, Zinneman HH, Hall WH. A review of 55 cases of multiple myeloma: emphasis on pneumonia and other infections as complications. Arch Intern Med. 1959;103:173–83.

    Article  CAS  Google Scholar 

  76. Hargreaves RM, Lea JR, Griffiths H, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48:260–6.

    Article  PubMed  CAS  Google Scholar 

  77. Snowdon L, Gibson J, Joshua DE. Frequncy of infection in plateau-phase multiple myeloma (Letter). Lancet. 1994;344:262.

    Article  PubMed  CAS  Google Scholar 

  78. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol. 1986;13:282–90.

    PubMed  CAS  Google Scholar 

  79. Broder S, Humphrey R, Durm M, et al. Impaired síntesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N Engl J Med. 1975;193:887–92.

    Article  Google Scholar 

  80. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic heamodialysis adult patients. A multicentre prospective survey. Nephrol Dial Transplant. 1995;10:377–81.

    PubMed  CAS  Google Scholar 

  81. Savage DG, Lindenbaum J, Garret TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982;96:47–50.

    PubMed  CAS  Google Scholar 

  82. Meyers BR, Hirschman SZ, Axelrod JA. Current pattern of infección in multiple myeloma. Am J Med. 1972;52:87–92.

    Article  PubMed  CAS  Google Scholar 

  83. Shaikh BS, Lombard RM, Appelbaum PC, et al. Changing pattern of infection in patients with multiple myeloma. Oncology. 1982;39:78–82.

    Article  PubMed  CAS  Google Scholar 

  84. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection in multiple myeloma. Am J Med. 1981;71:935–40.

    Article  PubMed  CAS  Google Scholar 

  85. Oken MM, Pomeroy C, Weisdorf D. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–8.

    Article  PubMed  CAS  Google Scholar 

  86. Salmon SE, Samal BA, Hayes DM, et al. Role of gammaglobulins for immunoprophylaxis in multiple myeloma. N Engl J Med. 1967;277:1336–40.

    Article  PubMed  CAS  Google Scholar 

  87. Richardson PG, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.

    Article  PubMed  CAS  Google Scholar 

  88. Gawler J. Neurological manifestations of myeloma and their management. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, editors. Myeloma. Biology and Management. 3rd ed. Philadelphia, PA: Elsevier; 2004. p. 269–93.

    Google Scholar 

  89. Posner JB. Back pain an epidural spinal cord compression. Med Clin North Am. 1987;71:185–201.

    PubMed  CAS  Google Scholar 

  90. Gawler J. Neurological manifestations of myeloma and their management. In: Malpas JS, Bergsagel DE, Kyle RA, editors. Myeloma: biology and management. Philadelphia, PA: Saunders, Elsevier; 2004. p. 269–95.

    Google Scholar 

  91. Husain MM, Metzer WS, Bidet EF. Multiple intraparenchymal brain plasmacytomas wit spontaneous intratumoral hemorrhage. Neurosurgery. 1987;20:619–23.

    Article  PubMed  CAS  Google Scholar 

  92. Woodruff RK, Ireton HJC. Multiple nerve palsies as the presenting feature of meningeal myelomatosis. Cancer. 1982;49:1710–2.

    Article  PubMed  CAS  Google Scholar 

  93. Fassas A, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with infavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45:291–300.

    Article  PubMed  Google Scholar 

  94. Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004;61:1423–9.

    Article  PubMed  Google Scholar 

  95. Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer. 2008;112:1562–7.

    Article  PubMed  Google Scholar 

  96. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with antiMAG IgM-M proteins and its relationship to immune therapies. Brain. 2000;123:710–7.

    Article  PubMed  Google Scholar 

  97. Latov N, Sherman WH. Therapy of neuropathy associated with antiMAG IgM monoclonal gammopathy with rituxan. Neurology. 1999;52(Suppl2):a551.

    Google Scholar 

  98. Levine TD, Pestronk A. IgM antibody related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701–4.

    Article  PubMed  CAS  Google Scholar 

  99. Cibeira MT, Rosiñol L, Ramiro L, et al. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol. 2006;77:486–92.

    Article  PubMed  CAS  Google Scholar 

  100. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–77.

    Article  PubMed  CAS  Google Scholar 

  101. Richardsson PG, Barlogie B, Berenson JR, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    Article  Google Scholar 

  102. Dispenzieri A. Complications of myeloma therapy. Hematol Oncol Clin North Am. 2007;21:1247–73.

    Article  PubMed  Google Scholar 

  103. Delforge M, Bladé J, Dimopoulos MA. Treatment-related peripheral neuropathy in multiple myeloma; the challenge continues. Lancet Oncol. 2010;11(11):1086–95.

    Article  PubMed  CAS  Google Scholar 

  104. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813–8.

    Article  PubMed  CAS  Google Scholar 

  105. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–8.

    Article  PubMed  CAS  Google Scholar 

  106. Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol. 1987;24:202–8.

    PubMed  CAS  Google Scholar 

  107. Woodruff RK, Malpas JS, Pastón AM, et al. Plasma cell leukemia: a report on 15 patients. Blood. 1978;52:839–45.

    PubMed  CAS  Google Scholar 

  108. Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukemia. Br J Haematol. 1994;88:754–9.

    Article  PubMed  CAS  Google Scholar 

  109. García-Sanz R, Orfao A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;95:1032–57.

    Google Scholar 

  110. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are very rare event in hypodiploid cases. Genes Chromosomes Cancer. 2003;38:234–9.

    Article  PubMed  Google Scholar 

  111. Tiedemann RE, González. Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–52.

    Article  PubMed  CAS  Google Scholar 

  112. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.

    Article  PubMed  CAS  Google Scholar 

  113. Morgan TK, Shuchun Z, Karen L, et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease. An immunohistochemical analysis. Am J Clin Pathol. 2006;126:545–51.

    Article  PubMed  Google Scholar 

  114. Avet-Loisseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, inter-phase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroup Francophone du Myeloma and the Group Francais de Cytogenetique Hematologique. Blood. 2001;97:822–5.

    Article  Google Scholar 

  115. Chang H, Sloan S, Li D, Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet. 2005;156:150–3.

    Article  PubMed  CAS  Google Scholar 

  116. Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48:624–36.

    Article  PubMed  CAS  Google Scholar 

  117. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myeloma. Blood. 2000;96:3560–8.

    PubMed  CAS  Google Scholar 

  118. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletion and mutations in multiple myeloma. Leuk Res. 2006;30:262–5.

    Article  PubMed  CAS  Google Scholar 

  119. Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leucemia. A surveillance, epidemiology and end results database analysis between 1973 and 2004. Cancer. 2009;115:5734–9.

    Article  PubMed  Google Scholar 

  120. Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95:804–9.

    Article  PubMed  Google Scholar 

  121. Katadritou E, Verrou E, Gastari V, et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res. 2008;32:1153–6.

    Article  CAS  Google Scholar 

  122. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285–90.

    Article  PubMed  CAS  Google Scholar 

  123. Gertz MA, Buadi FK. Plasma cell leukemia. Haematologica. 2010;95:705–7.

    Article  PubMed  CAS  Google Scholar 

  124. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.

    Article  PubMed  Google Scholar 

  125. Bourantas K. Nonsecretory multiple myeloma. Eur J Haematol. 1996;56:109–11.

    Article  Google Scholar 

  126. Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol. 1985;74:27–30.

    Article  PubMed  CAS  Google Scholar 

  127. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol. 1982;13:313–8.

    Article  PubMed  CAS  Google Scholar 

  128. Azar HA, Zaino EC, Pham TD, Yannopoulos K. “Non-secretory” plasma cell myeloma: observations on seven cases with electron microscopic studies. Am J Clin Pathol. 1972;58:618–29.

    Article  PubMed  CAS  Google Scholar 

  129. Turesson I, Grubb A. Non-secretory or low-secretory myeloma with intracellular kappa chains. Report of six cases and review of the literature. Acta Med Scand. 1878;204:445–51.

    Article  Google Scholar 

  130. Franchi F, Seminara P, Teodori L, et al. The non-producer plasma cell myeloma. Report of a case and review of the literature. Blut. 1986;52:281–7.

    Article  PubMed  CAS  Google Scholar 

  131. Mancilla R, Davis GL. Nonsecretory multiple myeloma. Immunohistologic and ultrastructral observations on two patients. Am J Med. 1977;63:1015–22.

    Article  PubMed  CAS  Google Scholar 

  132. River GL, Tewksbury DA, Fudenberg HH. “Nonsecretry” multiple myeloma. Blood. 1972;40:204–6.

    PubMed  CAS  Google Scholar 

  133. Stavem P, Froland SS, Haugen HF, et al. Nonsecretory myelomatosis without intracellular immunoglobulin. Immunofluorescent and ultramicroscopic studies. Scand J Haematol. 1976;17:89–95.

    Article  PubMed  CAS  Google Scholar 

  134. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115–23.

    Article  PubMed  Google Scholar 

  135. Durie BGM, Harouseau JL, San Miguel JF, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  PubMed  CAS  Google Scholar 

  136. Dispenzieri A, Kyle RA, Merlíni G, et al. International Myeloma working Group guidelines for serum-free Light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215–24.

    Article  PubMed  CAS  Google Scholar 

  137. Joyner MV, Cassuto JP, Dujardin P, et al. Non-excretory multiple myeloma. Br J Haematol. 1979;179(45):559–66.

    Article  Google Scholar 

  138. Rowe DS, Fahey JL. A new class of human immunoglobulins. II. Normal serum IgD. J Exp Med. 1965;121:185–99.

    Article  PubMed  CAS  Google Scholar 

  139. Ameis A, Ko HS, Pruzanski W. M components- a review of 1242 cases. Can Med Assoc J. 1976;114:889–92.

    PubMed  CAS  Google Scholar 

  140. Hobbs JR, Slot GM, Campbell CH, et al. Six cases of gamma-D myelomatosis. Lancet. 1966;2:614–8.

    Article  PubMed  CAS  Google Scholar 

  141. Jancelewicz Z, Takatsuki K, Sugai S, et al. IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975;135:87–93.

    Article  PubMed  CAS  Google Scholar 

  142. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol. 1991;47:262–7.

    Article  PubMed  CAS  Google Scholar 

  143. Fibbe WE, Jansen J. Prognostic factors in IgD myeloma. A study on 21 cases. Scand J Haematol. 1984;33:471–5.

    Article  PubMed  CAS  Google Scholar 

  144. Bladé J, Lust JA, Kyle RA. Immunoglobulin D myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.

    PubMed  Google Scholar 

  145. Fahey JL, Carbone PP, Rowe DS, et al. Plasma cell myeloma with D-myeloma protein (igD myeloma). Am J Med. 1968;45:373–80.

    Article  PubMed  CAS  Google Scholar 

  146. Kyle RA. IgD multiple myeloma: a cure at 21 years. Am J Hematol. 1988;29:41–3.

    Article  PubMed  CAS  Google Scholar 

  147. Annibali O, Petrucci MT, Del Bianco P, et al. IgM multiple myeloma: report of four cases and review of the literature. Leuk Lymphoma. 2006;47:1565–9.

    Article  PubMed  Google Scholar 

  148. Feyler S, O’Connor SJM, Rawstron AC, et al. IgM myeloma: a rare entity characterized by a CD20-, CD56- CD117- immunophenotype and the t(11;14). Br J Haematol. 2008;140:547–51.

    Article  PubMed  CAS  Google Scholar 

  149. Driedger H, Pruzanski W. Plasma cell neoplasia with sclerotic lesions: a study of five cases and review of the literature. Arch Intern Med. 1979;139:892–6.

    Article  PubMed  CAS  Google Scholar 

  150. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes: the POEMS syndrome. Report of two cases and review of the literature. Medicine (Baltimore). 1980;59:311–22.

    CAS  Google Scholar 

  151. Kelly Jr JJ, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology. 1983;33:202–10.

    Article  PubMed  Google Scholar 

  152. Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol. 1983;13:543–55.

    PubMed  CAS  Google Scholar 

  153. Kyle RA, Dyck PJ. Neuropathy associated with the monoclonal gammopathies. Chapter 67. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral Neuropathy. 3rd ed. Philadelphia, PA: W.B. Saunders; 1993. p. 1275–87.

    Google Scholar 

  154. Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A. Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest. 2008;133:969–74.

    Article  PubMed  Google Scholar 

  155. Dispenzieri A. POEMS syndrome. Blood Rev. 2007;21:285–99.

    Article  PubMed  Google Scholar 

  156. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104:3400–7.

    Article  PubMed  CAS  Google Scholar 

  157. Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008;80:397–406.

    Article  PubMed  Google Scholar 

  158. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol. 2008;144:86–94.

    Article  PubMed  Google Scholar 

  159. Chak LY, Cox RS, Bostwick DG, Hoppe RT. Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol. 1987;5:1811–5.

    PubMed  CAS  Google Scholar 

  160. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16:45–8.

    Google Scholar 

  161. Ellis PA, Colls BM. Solitary plasmacytoma of bone: clinical features, treatment and survival. Hematol Oncol. 1992;10:207–11.

    Article  PubMed  CAS  Google Scholar 

  162. Dagan R, Morris CG, Kirwan J, Mendenhall WM. Solitary plasmacytoma. Am J Clin Oncol. 2009;32:612–7.

    Article  PubMed  Google Scholar 

  163. Kumar S. Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol. 2008;83:695–6.

    Article  PubMed  Google Scholar 

  164. Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118–27.

    Article  PubMed  Google Scholar 

  165. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101:1715–7.

    Article  PubMed  CAS  Google Scholar 

  166. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free Light chains and solitary plasmacytoma of bone. Blood. 2006;108:1979–83.

    Article  PubMed  CAS  Google Scholar 

  167. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1:255–62.

    PubMed  CAS  Google Scholar 

  168. Meis JM, Butler JJ, Osborne BM, Ordónez NG. Solitary plasmacytoma of bone and extramedullary plasmacytomas. A clinicopathologic and immunohistochemical study. Cancer. 1987;59:1475–85.

    Article  PubMed  CAS  Google Scholar 

  169. Creach KM, Foote RL, Neben-Wittich MA, Kyle RA. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;73:789–94.

    Article  PubMed  Google Scholar 

  170. Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favourable prognosis. Leuk Lymphoma. 2006;47:1553–6.

    Article  PubMed  Google Scholar 

  171. Hewell GM, Alexanian R. Multiple myeloma in young patients. Arch Intern Med. 1976;84:441–3.

    CAS  Google Scholar 

  172. Bladé J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Arch Intern Med. 1996;156:1463–8.

    Article  PubMed  Google Scholar 

  173. Mitsiades CS, McMillin DW, Klippel S, et al. The role of bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007;21:1007–34.

    Article  PubMed  Google Scholar 

  174. Hideshima T, Chauban D, Hayashi T, et al. The biological sequelae of stem cell-derived factor 1-alpha in multiple myeloma. Mol Cancer Ther. 2002;1:539–44.

    PubMed  CAS  Google Scholar 

  175. Azar HA. Pathology of multiple myeloma and related growths. In: Azar HA, Potter M, editors. Multiple myeloma and related disorders. Hagerstown: Harper & Row; 1973. p. 1–85.

    Google Scholar 

  176. Churg J, Gordon AJ. Multiple myeloma. Lesions of the extra-osseous hematopoietic system. Am J Clin Pathol. 1950;20:934–45.

    PubMed  CAS  Google Scholar 

  177. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer. 1969;23:167–74.

    Article  PubMed  CAS  Google Scholar 

  178. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 172 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93:345–51.

    Article  PubMed  Google Scholar 

  179. Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50:230–5.

    Article  PubMed  CAS  Google Scholar 

  180. Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325–30.

    Article  PubMed  CAS  Google Scholar 

  181. Pérez Simón JA, Sureda A, Fernández-Avilés F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20:542–5.

    Article  PubMed  CAS  Google Scholar 

  182. Minnema MC, van de Donk NWCJ, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41(9):779–84.

    Article  PubMed  CAS  Google Scholar 

  183. Seizer R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs. medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and correlation to clinical outcome. Bone Marrow Transplant. 2004;34:1057–65.

    Article  Google Scholar 

  184. Katodritou E, Gastari V, Verrou E, et al. Extramedullary (EMP) relapse in inusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33:1137–40.

    Article  PubMed  CAS  Google Scholar 

  185. Belleari E, Bruzzone A. Inusual myeloma relapse after thalidomide therapy: the dark side of the moon. Leuk Res. 2009;33:1164–5.

    Article  Google Scholar 

  186. Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies—is the association real? Ann Oncol. 2007;18:7–12.

    Article  PubMed  CAS  Google Scholar 

  187. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread and treatment approach. J Clin Oncol. 2011;29:3805–12.

    Article  PubMed  Google Scholar 

  188. Fernández de Larrea C, Rosiñol L, Cibeira MT, Rozman M, Rovira M, Bladé J. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol. 2010;85:448–51.

    Article  Google Scholar 

  189. Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832–6.

    PubMed  Google Scholar 

  190. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide in multiple myeloma. Leuk Lymphoma. 2001;42:683–7.

    Article  PubMed  CAS  Google Scholar 

  191. Anagnostopoulos A, Hamilos G, Zorzou MP, et al. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2004;45:113–6.

    Article  PubMed  CAS  Google Scholar 

  192. Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005;90:278–9.

    PubMed  Google Scholar 

  193. Rosiñol L, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76:405–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona, 08036, Spain

    Joan Bladé Ph.D., M.D. & Laura Rosiñol Ph.D., M.D.

Authors
  1. Joan Bladé Ph.D., M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Rosiñol Ph.D., M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan Bladé Ph.D., M.D. .

Editor information

Editors and Affiliations

  1. Beth Israel Hospital, Cancer Center, St. Lukes-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Peter H. Wiernik

  2. , Department of Hematology, Imperial College of London, Du Cane Road 150, London, W12 0NN, United Kingdom

    John M. Goldman

  3. Continuum Cancer Centers, Department of Medicine, St. Luke's-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Janice P. Dutcher

  4. , Division of Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Robert A. Kyle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bladé, J., Rosiñol, L. (2013). Complications and Special Presentations of Plasma Cell Myeloma. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3764-2_34

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3763-5

  • Online ISBN: 978-1-4614-3764-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation